China’s state-run Global Times on Wednesday put the happiest possible spin on a dismaying Brazilian study that showed China’s Sinovac vaccine candidate for the Chinese coronavirus is only 50 percent effective.
Even though the results were far below the 80 percent effectiveness originally claimed — and that, in turn, was far below the estimates for vaccines like the one made by Pfizer — the Global Times declared it was “good enough.”
Sao Paulo-based Instituto Butantan, the research institute developing the Sinovac product for distribution in Brazil, announced last week that clinical tests showed it to be 78 percent effective overall. On Tuesday, the institute revealed at a press conference that late-stage trials involving over 12,000 volunteers showed it was only 50.38 percent effective overall, although the Brazilian researchers said it was much more effective at treating “severe” cases of Chinese coronavirus than mild infections.
“This is an efficient vaccine. We